Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin for open abdomen midline closure
2025-522410-23-00Phase 4Authorised
- Sponsor
- Hospital Universitario La Paz
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in open abdomen (OA) comparing Dysport with Placebo (0.9% saline) (2 arms). Primary endpoint: Primary fascial closure without permanent bridging mesh. Planned start Mar 2026; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
open abdomen (OA)
Beyond the preview
Go deeper on 2025-522410-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522410-23-00.